OCGN Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of 49.9%. Ocugen, Inc.'s return on equity of -345.08% beat CorMedix, Inc.'s return on equity of 95.25%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 363.92%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 106.06%. Given that Ocugen, Inc. has higher upside potential than CorMedix, Inc., analysts believe Ocugen, Inc. is more attractive than CorMedix, Inc..

Ocugen, Inc. has a beta of 2.750, which suggesting that the stock is 175.048% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.308, suggesting its more volatile than the S&P 500 by 30.754%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Ocugen, Inc.'s net income of -$20.1M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 106.48x versus 2.43x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Keros Therapeutics, Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of -51.05%. Ocugen, Inc.'s return on equity of -345.08% beat Keros Therapeutics, Inc.'s return on equity of 9.94%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 363.92%. On the other hand Keros Therapeutics, Inc. has an analysts' consensus of $23.00 which suggests that it could grow by 65.35%. Given that Ocugen, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Ocugen, Inc. is more attractive than Keros Therapeutics, Inc..

Ocugen, Inc. has a beta of 2.750, which suggesting that the stock is 175.048% more volatile than S&P 500. In comparison Keros Therapeutics, Inc. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.759%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. Keros Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than Keros Therapeutics, Inc. quarterly revenues of $14.3M. Ocugen, Inc.'s net income of -$20.1M is lower than Keros Therapeutics, Inc.'s net income of -$7.3M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while Keros Therapeutics, Inc.'s PE ratio is 9.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 106.48x versus 2.29x for Keros Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of -14.25%. Ocugen, Inc.'s return on equity of -345.08% beat MannKind Corp.'s return on equity of --.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 363.92%. On the other hand MannKind Corp. has an analysts' consensus of $7.72 which suggests that it could grow by 154.44%. Given that Ocugen, Inc. has higher upside potential than MannKind Corp., analysts believe Ocugen, Inc. is more attractive than MannKind Corp..

Ocugen, Inc. has a beta of 2.750, which suggesting that the stock is 175.048% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.834, suggesting its less volatile than the S&P 500 by 16.605%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than MannKind Corp. quarterly revenues of $112M. Ocugen, Inc.'s net income of -$20.1M is lower than MannKind Corp.'s net income of -$15.9M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 180.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 106.48x versus 2.72x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Phathom Pharmaceuticals, Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of -36.73%. Ocugen, Inc.'s return on equity of -345.08% beat Phathom Pharmaceuticals, Inc.'s return on equity of --.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 363.92%. On the other hand Phathom Pharmaceuticals, Inc. has an analysts' consensus of $23.50 which suggests that it could grow by 105.06%. Given that Ocugen, Inc. has higher upside potential than Phathom Pharmaceuticals, Inc., analysts believe Ocugen, Inc. is more attractive than Phathom Pharmaceuticals, Inc..

Ocugen, Inc. has a beta of 2.750, which suggesting that the stock is 175.048% more volatile than S&P 500. In comparison Phathom Pharmaceuticals, Inc. has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.056%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. Phathom Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than Phathom Pharmaceuticals, Inc. quarterly revenues of $57.6M. Ocugen, Inc.'s net income of -$20.1M is higher than Phathom Pharmaceuticals, Inc.'s net income of -$21.1M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while Phathom Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 106.48x versus 4.77x for Phathom Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.